The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)

September 19, 2022toSeptember 20, 2022

由泌尿外科协会与泌尿外科肿瘤学会(SUO)合作提出。

SUO strongly encourages that fellows participate in at least one SUO-sponsored educational course as available during their fellowship in addition to attending the Annual/Winter Meeting and the AUA/Spring Meeting. This educational course satisfies this recommendation.

赠送的CME课程!

Monday, September 19 - Tuesday, September 20, 2022 | 4 - 7 p.m. Eastern Time

Join Course Directors, Michael S. Cookson, MD, MMHC, FACS & David F. Jarrard, MD for an educational initiative in advanced prostate cancer.

As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). Topics will include the latest on Genetic Testing in Advanced Prostate Cancer and the Role of Immunotherapy and PARP Inhibitors.

Designed for residents, fellows and APPs as well as urologists and other health care providers who care for patients with prostate cancer, this interactive forum will focus on the application of knowledge with case studies and small group discussion integrated throughout the day. A flipped classroom approach will be utilized. Register early to receive the Prework Library which will be available to all registered participants by August 2022. Participants will be expected to complete the Prework Library in advance of attending the live course - complete the prework on your own time, at your convenience. Then, come prepared on September 19-20 to actively engage with peers as you apply what you've learned.

Pre-registration is required as space is limited.

Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer. This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer.

The Live Forum will cover the following topics*:

  • Identification of High Risk Disease and Initial Management of Biochemical Recurrence
  • Imaging of Advanced Prostate Cancer
  • M0 CRPC: Treatment Options and Goals of Therapy
  • Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
  • Genetic Testing in Advanced Prostate Cancer
  • Bone Health and Radionuclide Therapy
  • Role of Immunotherapy and PARP Inhibitors
  • Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions

*Visit the program tab for full details.

Acknowledgements

This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Exact Sciences Corporation
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lantheus Medical Imaging
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologist
  • Resident
  • Fellow
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)

Learning Objectives

At the conclusion of this activity, participants will be able to:

PRACTICE GAP #1 (DISEASE STATE)

  1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
  2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
  4. 描述新诊断的mHSPC的治疗方案和结果。
  5. 解释CRPC对M0和M1管理的影响。
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC.

PRACTICE GAP #2 (GUIDELINES)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with M0 CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  5. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

PRACTICE GAP #3 (ANDROGEN AXIS)

  1. 确定已批准的用于CRPC治疗的雄激素生物合成和受体阻滞剂。
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. 预测、管理和治疗CRPC治疗中针对雄激素轴的治疗干预的不良事件。
  4. Discuss new uses for androgen axis agents in M0 CRPC.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND CO-MORBIDITY)

  1. Identify approved chemotherapeutics, immunotherapy and PARP Inhibitors for mCRPC.
  2. Describe indications and contraindications for chemotherapy, immunotherapy and PARP Inhibitors in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Identify germline and somatic mutations and implications for treatment in mCRPC including indications for PAPR Inhibitors and pembrolizumab.
  5. Discuss treatment sequencing in the advanced, metastatic and CRPC disease state.

PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. 讨论已知的与雄激素生物合成抑制剂和放射性核素治疗相关的不良事件。

PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)

  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
  3. Review the role of palliative care and supportive services in the management of late stage CRPC.
Course summary
Available credit:
  • 5.75AMA PRA Category 1 Credit™
  • 5.75Non-Physician Participation
Course opens:
03/11/2022
Course expires:
09/20/2025
Event starts:
09/19/2022 - 4:00pm EDT
Event ends:
09/20/2022 - 7:00pm EDT
Add to calendar:
Rating:
0

The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion

Part I – Monday, September 19, 2022

All times are listed inEastern Time

Agenda
4:00 — 4:05 p.m. Welcome
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
4:05 — 4:10 p.m. Pre-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
Session I
4:10 — 4:30 a.m. Identification of High-Risk Disease and Initial Management of Biochemical Recurrence
Stephen A. Boorjian, MD
4:30 — 4:50 p.m. Imaging of Advanced Prostate Cancer and Impact on Cancer Management
Kelly L. Stratton, MD
4:50 — 5:05 p.m. M0 CRPC: Treatment Options and Goals of Therapy
Michael S. Cookson, MD, MMHC
5:05 — 5:55 p.m. Case-based Roundtable Discussions: Recurrent and nonmetastatic CRPC
  • Case #1 – BCR & Novel PET Imaging –Stephen A. Boorjian, MD
  • Case #2 – M0 CRPC –Michael S. Cookson, MD, MMHC
Roundtable Discussants: All Faculty
下午5:55 - 6:15 Manipulating the Androgen Axis: New Agents in mHSPC and CRPC
David F. Jarrard, MD
6:15 — 6:35 p.m. Genetic Testing in Advanced Prostate Cancer
Leonard Gomella, MD, FACS
6:35 — 6:55 p.m. mHSPC: Maximal Androgen Targeted vs Chemohormonal Therapy for mHSPC and Management of Oligometastatic Disease
David F. Jarrard, MD & Joshua M. Lang, MD
6:55 — 7:00 p.m. Post-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD

Part II – Tuesday, September 20, 2022
4:00 — 4:05 p.m. Welcome Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
4:05 — 4:10 p.m. Pre-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
Session II
4:10 — 4:30 p.m. Bone Health and Radionuclide Therapy
Stephen A. Boorjian, MD
4:30 — 4:50 p.m. Role of Immunotherapy and PARP Inhibitors
Alicia Morgans, MD, MPH
4:50 — 5:40 p.m. Case-based Roundtable Discussions: Chemotherapy-naïve metastatic CRPC
  • Case #3 - Early M1 CRPC (Docetaxel vs. AR vs. Sipleucel-T) –Kelly L. Stratton, MD
  • Case #4 - Advanced M1 CRPC (Docetaxel and Ra-223) –Alicia Morgans, MD, MPH

Roundtable Discussants: All Faculty
Session III
5:40 — 6:05 p.m. Role of Chemotherapy, Treatment Sequencing in mCRPC and Future Directions
Joshua M. Lang, MD
6:05 — 6:55 p.m. Case-based Roundtable Discussions: Post-Chemotherapy metastatic CRPC
  • Case #5 - Role of Genetic Testing in Advanced M1 CRPC (Immunotherapy or PARP Inhibitors) –Leonard Gomella, MD, FACS
  • Case #6 - M1 CRPC Post-docetaxel, Neuroendocrine Cancer and End-of-Life Care –Joshua M. Lang, MD

Roundtable Discussants: All Faculty
6:55 — 7:00 p.m. Post-Test
Michael S. Cookson, MD, MMHC & David F. Jarrard, MD
Virtual Only
United States

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Co-director(s)

Michael Cookson, MD,MHA

has afinancial relationship (Consultant or Advisor (Oncology)) with Prokarium; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Pfizer; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Bayer Healthcare Pharmaceuticals; .
has afinancial relationship (Health Publishing (Oncology)) with BioPharm Communications; .
has afinancial relationship (Consultant or Advisor (Oncology)) with TesoRx Pharma LLC; .
has afinancial relationship (Consultant or Advisor (Oncology)) with MJH LifeSciences; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Pacifice Edge Diagnostics; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Astellas Pharma, Inc.; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Nonagen Bioscience Corp.; .
has afinancial relationship (Meeting Participant or Lecturer (Oncology)) with Clinical Education Alliance, LLC; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Myovant Sciences; .

David Jarrard, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

Stephen Boorjian, MD

has afinancial relationship (Consultant or Advisor (Oncology)) with Prokarium; .
has afinancial relationship (Consultant or Advisor (Oncology)) with ArTara; .
has afinancial relationship (Consultant or Advisor (Oncology)) with FerGene; .
has afinancial relationship (Consultant or Advisor (General Urology)) with Ferring; .

Leonard Gomella, MD

has afinancial relationship (Consultant or Advisor (Oncology)) with Lantheus; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck Pharmaceuticals; .